Minerva Surgical (Minerva Surgical) Momentum Rank : 0 (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Momentum Rank?

Minerva Surgical has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Minerva Surgical Momentum Rank Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Surgical (Minerva Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4255 Burton Drive, Santa Clara, CA, USA, 95054

Website

https://www.minervasurgical.com

Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.

Executives

Daniel Cohen	director	C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p.	10 percent owner	2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger	director, 10 percent owner	221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen	director, officer: Chief Executive Officer	C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung	director	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper	director, officer: President and CEO	3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi	officer: VP Medical Affairs	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux	officer: COO	C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung	officer: CFO	1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt	director	SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson	director	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202